Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 6/20 | 0.59 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.56 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | XDH | P47989 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1177647 | 0.87 | IDO1 (0.59) | IDO1CDK5DYRK1ACDK5R1ADORA2A | |
| SCHEMBL1176947 | 0.81 | KDM4E (0.45) | IDO1HSD17B10KDM4EALDH1A1MEN1 | |
| SCHEMBL14498361 | 0.78 | IDO1 (0.51) | IDO1CDK5DYRK1ACDK5R1LMNA | |
| SCHEMBL7011406 | 0.74 | ADORA2A (0.70) | CDK5DYRK1ACDK5R1LMNAADORA2A | |
| SCHEMBL8565521 | 0.69 | ADORA2A (0.52) | CDK5DYRK1ACDK5R1LMNAADORA2A | |
| SCHEMBL7999219 | 0.69 | IDO1 (0.45) | IDO1XDHALDH1A1TDO2 | |
| SCHEMBL1177330 | 0.69 | IDO1 (0.45) | IDO1HSD17B10KDM4EALDH1A1TDO2 | |
| SCHEMBL3544893 | 0.68 | ADORA2A (0.62) | CDK5DYRK1ACDK5R1LMNAADORA2A | |
| SCHEMBL6072337 | 0.68 | CDK5 (0.54) | CDK5DYRK1ACDK5R1LMNAADORA2A | |
| SCHEMBL935581 | 0.67 | ALDH1A1 (0.67) | IDO1HSD17B10KDM4EXDHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2556856-B1 | 6-Cyano-substituted Pyrido[2,3-d]pyrimidines as Adenosin Rezeptor Ligands for the Treatment of Cardiovascular Diseases | BAYER IP GMBH (DE) | 2015-02-25 | — | — | EP | disclosed |
| US-8618119-B2 | Fused cyanopyridines and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-31 | — | — | US | disclosed |
| EP-2556831-A1 | 3,4-Dihydro-4-oxo-5-aryl-pyrido[2,3-d]pyrimidine-6-carbonitriles as Adenosin Receptor Ligands for Treatment of Cardiovascular Diseases | Bayer Intellectual Property GmbH (DE) | 2013-02-13 | — | — | EP | disclosed |
| EP-2556856-A1 | 6-Cyano-substituted Pyrido[2,3-d]pyrimidines as Adenosin Rezeptor Ligands for the Treatment of Cardiovascular Diseases | Bayer Intellectual Property GmbH (DE) | 2013-02-13 | — | — | EP | disclosed |
| EP-2555763-A1 | VIRAL INHIBITOR COMPOSITIONS FOR IN VIVO THERAPEUTIC USE COMPRISING A COMBINATION OF (-) -CARVONE, GERANIOL AND A FURTHER ESSENTIAL OIL COMPONENT | Cesa Alliance S.A. (LU) | 2013-02-13 | — | — | EP | disclosed |
| US-20110046162-A1 | FUSED CYANOPYRIDINES AND THE USE THEREOF | Bayer Schering Pharma (DE) | 2011-02-24 | — | — | US | disclosed |
| EP-2234980-A1 | FUSED CYNOPRYRIDINES AND THE USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009080198-A1 | FUSED CYNOPRYRIDINES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046162-A1 | FUSED CYANOPYRIDINES AND THE USE THEREOF | TNNI3, QDPR, RYR2 | IDO1 4726/4885CDK5 671/4885DYRK1A 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.